This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Sartar Therapeutics Ltd. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Harri Sihto: Innovator in Cancer Treatment
Introduction
Harri Sihto is a notable inventor based in Helsinki, Finland. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on compositions that utilize phosphodiesterase inhibitors for the treatment of solid tumors in human patients.
Latest Patents
Harri Sihto holds a patent for "Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient." This invention relates to a composition that includes a phosphodiesterase inhibitor, such as anagrelide or a salt thereof. The composition is intended for the treatment of solid tumors, including gastrointestinal stromal tumors (GIST) or liposarcomas, which express phosphodiesterase 3 enzymes in human patients. He has 1 patent to his name.
Career Highlights
Harri Sihto is currently associated with Sartar Therapeutics Ltd., where he continues to advance his research in cancer therapies. His work has the potential to significantly impact the treatment options available for patients suffering from various types of solid tumors.
Collaborations
Some of his notable coworkers include Olli-Pekka Pulkka and Olli Kallioniemi. Their collaborative efforts contribute to the innovative environment at Sartar Therapeutics Ltd.
Conclusion
Harri Sihto's contributions to cancer treatment through his patented inventions highlight his role as a key innovator in the field. His work continues to pave the way for new therapeutic options for patients facing challenging diagnoses.